SUSQUEHANNA INTERNATIONAL GROUP, LLP - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 62 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q1 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
SUSQUEHANNA INTERNATIONAL GROUP, LLP ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2022$8,000
-63.6%
34,223
-18.2%
0.00%
Q2 2022$22,000
-51.1%
41,813
+91.8%
0.00%
Q1 2022$45,000
-95.9%
21,800
-91.6%
0.00%
Q4 2021$1,088,000
-42.3%
260,800
+28.7%
0.00%
Q3 2021$1,884,000
-63.2%
202,590
-28.7%
0.00%
Q2 2021$5,114,000283,9720.00%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q1 2022
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 471,878$8,499,0006.04%
BALDWIN BROTHERS LLC/MA 44,116$795,0000.09%
DOWLING & YAHNKE LLC 15,806$285,0000.02%
INVERNESS COUNSEL LLC /NY/ 13,307$240,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 15,000$270,0000.01%
Cutler Group LLC / CA 4,200$75,0000.00%
MetLife Investment Management, LLC 10,805$194,5980.00%
HAP Trading, LLC 13,900$64,0000.00%
METROPOLITAN LIFE INSURANCE CO/NY 8,272$148,9790.00%
Ameritas Investment Partners, Inc. 1,867$34,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders